Pharma in silica's mission is to improve the cancer patient outcomes with high-innocuity chemotherapy solutions. The preclinical-stage, Québec City-based, nimble and intangible-asset company intends to file an IND by the end of 2021.
in silica™ is a proprietary transport and liberation technology. Its functionalized and porous silica spheres promise distinctive advantages over established nanomedicine technologies (clean formulation, reduced exposure, improved on-target rate, efficient TME and in-tumour liberation).
The in silica™ drug carrier
The versatility of silica’s chemistry is likely to grant the in silica™ drug carrier distinctive advantages over established nanomedicines such as liposomes and protein-linked drugs.
A silica sphere can be engineered for single or multiple-drug administration, optimal nano or micro size, simple and safe formulation, leakage-free and long-duration circulation, high-tumour selectivity and environment-triggered, tuneable release. Each vehicle is designed to suit the drug cargo and the cancer it treats. The resulting solution is scalable under GMP, cost-effective and patentable.
Pharma in silica currently develops safer versions of off-patent chemotherapy agents such as paclitaxel and docetaxel for NSCLC. Other development opportunities will be pursued via out-licensing, partnering and project-specific financing.
A novel and proprietary drug carrier
- Sophisticated chemistry.
- Clean synthesis.
- GLP/GMP compatible.